These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8342120)
21. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Horwitz AH; Leigh SD; Abrahamson S; Gazzano-Santoro H; Liu PS; Williams RE; Carroll SF; Theofan G Protein Expr Purif; 1996 Aug; 8(1):28-40. PubMed ID: 8812832 [TBL] [Abstract][Full Text] [Related]
23. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Schultz H Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria. Kung AH; Ammons WS; Lin Y; Kohn FR Prog Clin Biol Res; 1994; 388():255-63. PubMed ID: 7831363 [No Abstract] [Full Text] [Related]
25. Role of endotoxin in acute inflammation induced by gram-negative bacteria: specific inhibition of lipopolysaccharide-mediated responses with an amino-terminal fragment of bactericidal/permeability-increasing protein. Kohn FR; Kung AH Infect Immun; 1995 Jan; 63(1):333-9. PubMed ID: 7806373 [TBL] [Abstract][Full Text] [Related]
26. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056 [TBL] [Abstract][Full Text] [Related]
27. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. Levy O; Ooi CE; Elsbach P; Doerfler ME; Lehrer RI; Weiss J J Immunol; 1995 May; 154(10):5403-10. PubMed ID: 7730641 [TBL] [Abstract][Full Text] [Related]
28. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro. Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661 [TBL] [Abstract][Full Text] [Related]
29. Alteration of the pharmacokinetics of small proteins by iodination. Bauer RJ; Leigh SD; Birr CA; Bernhard SL; Fang M; Der K; Ihejeto NO; Carroll SF; Kung AH Biopharm Drug Dispos; 1996 Dec; 17(9):761-74. PubMed ID: 8968529 [TBL] [Abstract][Full Text] [Related]
30. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Barriere SL; Guglielmo BJ Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812 [TBL] [Abstract][Full Text] [Related]
31. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. Babalola CP; Nightingale CH; Nicolau DP J Antimicrob Chemother; 2004 Jun; 53(6):1098-100. PubMed ID: 15128727 [TBL] [Abstract][Full Text] [Related]
32. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. Marra MN; Wilde CG; Griffith JE; Snable JL; Scott RW J Immunol; 1990 Jan; 144(2):662-6. PubMed ID: 2295804 [TBL] [Abstract][Full Text] [Related]
33. Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. Mannion BA; Kalatzis ES; Weiss J; Elsbach P J Immunol; 1989 Apr; 142(8):2807-12. PubMed ID: 2539411 [TBL] [Abstract][Full Text] [Related]
34. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. Marra MN; Wilde CG; Collins MS; Snable JL; Thornton MB; Scott RW J Immunol; 1992 Jan; 148(2):532-7. PubMed ID: 1729370 [TBL] [Abstract][Full Text] [Related]
35. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464 [TBL] [Abstract][Full Text] [Related]
36. Bactericidal/permeability-increasing protein for severe meningococcal sepsis. Schultz H; Csernok E; Gross WL Lancet; 1998 Feb; 351(9101):526. PubMed ID: 9482480 [No Abstract] [Full Text] [Related]
37. Effects of recombinant bactericidal, permeability-increasing protein on bacterial translocation and pulmonary neutrophil sequestration in burned mice. Rennekampff OH; Tenenhaus M; Hansbrough J; Kiessig V; Zapata-Sirvent RL J Burn Care Rehabil; 1997; 18(1 Pt 1):17-21. PubMed ID: 9063782 [TBL] [Abstract][Full Text] [Related]
38. The recombinant 23-kDa N-terminal fragment of bactericidal/permeability-increasing protein (rBPI23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Lechner AJ; Lamprech KE; Johanns CA; Matuschak GM Shock; 1995 Oct; 4(4):298-306. PubMed ID: 8564560 [TBL] [Abstract][Full Text] [Related]
39. Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Appelmelk BJ; An YQ; Thijs BG; MacLaren DM; de Graaff J Infect Immun; 1994 Aug; 62(8):3564-7. PubMed ID: 8039930 [TBL] [Abstract][Full Text] [Related]
40. Human lipopolysaccharide-binding protein potentiates bactericidal activity of human bactericidal/permeability-increasing protein. Horwitz AH; Williams RE; Nowakowski G Infect Immun; 1995 Feb; 63(2):522-7. PubMed ID: 7822017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]